Mestinon (Pyridostigmine Bromide)

Pyridostigmine inhibits the enzyme acetylcholinesterase, which normally breaks down acetylcholine at the neuromuscular junction. By slowing this breakdown, more acetylcholine remains available to stimulate muscle receptors, enhancing the transmission of nerve signals to skeletal muscles and improving contraction strength.

The dosage of Mestinon is individualized and set by a qualified prescriber based on the patient’s condition, severity, and response. Physicians typically start with a low dose and adjust gradually, monitoring clinical improvement and any side effects.

The safety of pyridostigmine during pregnancy and lactation has not been definitively established, and it is classified as a category unknown. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider.

To order Mestinon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mestinon (pyridostigmine) and neostigmine belong to the same drug class, but pyridoxostigmine has a longer duration of action and is typically taken orally, whereas neostigmine is often administered intravenously for rapid effect. Choice of agent depends on clinical setting, required onset speed, and patient tolerance.

Mestinon tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in a refrigerator or freezer.

Mestinon is taken orally, usually with a glass of water. It can be administered with or without food, but consistent timing relative to meals helps maintain stable blood levels. Patients should follow the prescriber’s instructions regarding frequency and any dose adjustments.

The most serious adverse events include cholinergic crisis, which can cause severe muscle weakness, respiratory failure, and paralysis; marked bradycardia that may lead to hypotension; and severe bronchospasm, especially in patients with underlying respiratory disease. Immediate medical attention is required if these occur.

Mestinon is contraindicated in individuals with known hypersensitivity to pyridostigmine or any excipients, those with mechanical intestinal obstruction, severe asthma or chronic obstructive pulmonary disease, and patients with uncontrolled cardiac arrhythmias. A thorough medical history should be reviewed before initiating therapy.